Latest Articles
- Bioterrorism: What practicing physicians can do
Given the specter of biological terrorism, the medical system has much to learn and much to do to prepare.
Our new understanding of pulmonary alveolar proteinosis: What an internist needs to knowRecent advances point to a defect in granulocyte-macrophage colony stimulating factor (GM-CSF) as a cause of this disease. New treatments are under study.
- Chronic myelogenous leukemia: The news you have and haven’t heard
One major advance in treating CML was widely publicized. Another, although equally important, was not.
- COX-2 inhibitors: Balancing the hope, the hype, and the concern
When all is said and done, the choice rests with the individual prescribing physician.
- Role of alendronate and risedronate in preventing and treating osteoporosis
A review of the efficacy and use of the two oral bisphosphonates approved for preventing and treating osteoporosis.
- Management of primary headache: Serendipity and science
A capsule summary of the current management of migraine, chronic tension headache, and cluster headache.
- Cox - 2 Inhibitors and Cardiovascular Risk
Unless a clear cause-and-effect relationship can be proved between COX-2 inhibitors and cardiovascular events, we should go on using these drugs.
- Cox - 2 Inhibitors and Cardiovascular Risk
Even if we do not know with certainty whether COX-2 inhibitors increase the risk of cardiovascular events, we need to incorporate this concern into our practice.